In 2022, about nine months before Novo Holdings first reached out to Catalent about a potential deal, the contract manufacturer was in talks with another
Sanofi’s “new chapter” will involve job cuts and scrapping several oncology research projects, a spokesperson confirmed to Endpoints News on Friday. The pharma giant is
After upending Illumina’s leadership, activist investor Carl Icahn appears to be backing off. According to a proxy filing Thursday, Icahn’s director on Illumina’s board won’t
While state Medicaid programs have increasingly loosened coverage restrictions on hepatitis C drugs in recent years, a team of researchers at Harvard University recently published
Bristol Myers Squibb and 2seventy bio’s CAR-T therapy Abecma will now be available to earlier-stage multiple myeloma patients. The drug, also known as ide-cel, won
LENZ Therapeutics is clear on the benefits of pre-commercial marketing for its presbyopia eye drops, bolstered by positive Phase 3 news this week. The new
AstraZeneca is moving its blockbuster cancer drug Imfinzi into earlier stages of small cell lung cancer, a disease that has not seen innovation in standard
Protara Therapeutics raises $45M private placement: The oversubscribed financing transaction is set to close April 10. The proceeds should extend the company’s runway through 2026
(This story is from our new Health Tech newsletter. If you’d like to sign up, just click here.) Teladoc Health’s CEO Jason Gorevic is stepping
Outside biotech money isn’t pouring into China like it used to. In 2020 and 2021, venture investors put nearly $8 billion into Chinese biopharmas. But